相关实验视频

Updated: Jun 9, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

介素-12的输送策略和瘤免疫疗法的进展

Chunyan Dong¹, Dejiang Tan¹, Huimin Sun¹

¹State Key Laboratory of Drug Regulatory Sciences, National Institutes for Food and Drug Control, Beijing 102629, China.

Current issues in molecular biology

|October 25, 2024

概括

介质蛋白-12 (IL-12) 在癌症免疫疗法方面显示出前景. 包括病毒和非病毒载体在内的新型传递策略旨在提高其有效性并减少对增强抗瘤反应的毒性.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
生物技术是生物技术.

背景情况:

介乐-12 (IL-12) 是一种细胞因子,有可能增强抗瘤免疫反应.
在临床试验中,重组IL-12面临着显著毒性和有限疗效的挑战.
开发有效的输送策略对于利用IL-12的治疗潜力至关重要.

研究的目的:

系统地审查用于将IL-12输送到瘤组织的各种策略.
讨论IL-12的抗瘤作用,单独或组合疗法,基于不同的输送方法.
为了突出克服IL-12的毒性和有效性限制的进展.

主要方法:

探索IL-12修饰策略,包括与细胞外矩阵蛋白和免疫因子的融合.
对局部IL-12表达的病毒载体传递系统 (例如,瘤病毒,腺病毒,天花病毒) 的评估.
评估非病毒载体,如脂质纳米颗粒,以及针对IL-12输送的细胞载体.

主要成果:

通过病毒载体的局部IL-12表达可以诱导有效的抗瘤免疫力,同时避免全身毒性.
融合策略和先进的药物输送系统,如脂质纳米颗粒,有望提高治疗潜力.
细胞载体提供了一种替代方法,可以有效地将治疗物质传递给瘤.

结论:

目前正在开发各种输送策略,以提高IL-12在癌症治疗中的有效性和安全性.
有针对性的传递系统,特别是病毒载体,可以减轻全身毒性,增强抗瘤免疫反应.
对这些输送方法的进一步研究对于优化基于IL-12的癌症免疫疗法至关重要.

关键词:

在IL-12中,IL-12是最重要的.系统交付系统的交付系统.免疫疗法免疫疗法

更多相关视频

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...